Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time

Marlene Williams, Ladina S. Ng'alla

Research output: Contribution to journalArticle

Abstract

Background: Heparin is used in the treatment of venous and arterial thromboembolic events, including unstable angina. Once unfractionated heparin is discontinued during the acute phase of unstable angina, it has been demonstrated that the disease process may be reactivated within hours. It is hypothesized that this reactivation may be a result of direct platelet activation by heparin that can linger even after the drug itself has been stopped. Prior studies have shown that heparin can either increase or decrease platelet activation. More recent studies have also shown conflicting effects of unfractionated heparin on PFA-100 testing. Methods: We studied the in-vitro effects of unfractionated heparin on platelet function and PFA-100 testing. Unfractionated heparin was incubated with whole blood taken from 18 healthy volunteers. Platelet activation and aggregation was assessed with and without the presence of heparin. Results: Platelet aggregation and activation were increased in the presence of heparin. Unfractionated heparin also significantly prolonged collagen/adenosine diphosphate closure time but did not affect collagen/epinephrine closure time. Conclusions: Unfractionated heparin leads to direct platelet activation and increases platelet aggregation in vitro. Unfractionated heparin causes prolongation of the collagen/adenosine diphosphate closure time in PFA-100 testing, possibly as a result of direct binding to von Willebrand factor in solution and interference with von Willebrand factor-glycoprotein Ib binding.

Original languageEnglish (US)
Pages (from-to)273-280
Number of pages8
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume10
Issue number4
DOIs
StatePublished - Dec 2005

Fingerprint

Platelet Activation
Heparin
Therapeutics
Platelet Aggregation
Collagen
Unstable Angina
von Willebrand Factor
Adenosine Diphosphate
Platelet Glycoprotein GPIb-IX Complex
Epinephrine
Healthy Volunteers
Blood Platelets

Keywords

  • Heparin
  • PFA testing
  • Platelet function

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time. / Williams, Marlene; Ng'alla, Ladina S.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 4, 12.2005, p. 273-280.

Research output: Contribution to journalArticle

@article{cb055537b06f4e6a8dc987ec34b99308,
title = "Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time",
abstract = "Background: Heparin is used in the treatment of venous and arterial thromboembolic events, including unstable angina. Once unfractionated heparin is discontinued during the acute phase of unstable angina, it has been demonstrated that the disease process may be reactivated within hours. It is hypothesized that this reactivation may be a result of direct platelet activation by heparin that can linger even after the drug itself has been stopped. Prior studies have shown that heparin can either increase or decrease platelet activation. More recent studies have also shown conflicting effects of unfractionated heparin on PFA-100 testing. Methods: We studied the in-vitro effects of unfractionated heparin on platelet function and PFA-100 testing. Unfractionated heparin was incubated with whole blood taken from 18 healthy volunteers. Platelet activation and aggregation was assessed with and without the presence of heparin. Results: Platelet aggregation and activation were increased in the presence of heparin. Unfractionated heparin also significantly prolonged collagen/adenosine diphosphate closure time but did not affect collagen/epinephrine closure time. Conclusions: Unfractionated heparin leads to direct platelet activation and increases platelet aggregation in vitro. Unfractionated heparin causes prolongation of the collagen/adenosine diphosphate closure time in PFA-100 testing, possibly as a result of direct binding to von Willebrand factor in solution and interference with von Willebrand factor-glycoprotein Ib binding.",
keywords = "Heparin, PFA testing, Platelet function",
author = "Marlene Williams and Ng'alla, {Ladina S.}",
year = "2005",
month = "12",
doi = "10.1177/107424840501000407",
language = "English (US)",
volume = "10",
pages = "273--280",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time

AU - Williams, Marlene

AU - Ng'alla, Ladina S.

PY - 2005/12

Y1 - 2005/12

N2 - Background: Heparin is used in the treatment of venous and arterial thromboembolic events, including unstable angina. Once unfractionated heparin is discontinued during the acute phase of unstable angina, it has been demonstrated that the disease process may be reactivated within hours. It is hypothesized that this reactivation may be a result of direct platelet activation by heparin that can linger even after the drug itself has been stopped. Prior studies have shown that heparin can either increase or decrease platelet activation. More recent studies have also shown conflicting effects of unfractionated heparin on PFA-100 testing. Methods: We studied the in-vitro effects of unfractionated heparin on platelet function and PFA-100 testing. Unfractionated heparin was incubated with whole blood taken from 18 healthy volunteers. Platelet activation and aggregation was assessed with and without the presence of heparin. Results: Platelet aggregation and activation were increased in the presence of heparin. Unfractionated heparin also significantly prolonged collagen/adenosine diphosphate closure time but did not affect collagen/epinephrine closure time. Conclusions: Unfractionated heparin leads to direct platelet activation and increases platelet aggregation in vitro. Unfractionated heparin causes prolongation of the collagen/adenosine diphosphate closure time in PFA-100 testing, possibly as a result of direct binding to von Willebrand factor in solution and interference with von Willebrand factor-glycoprotein Ib binding.

AB - Background: Heparin is used in the treatment of venous and arterial thromboembolic events, including unstable angina. Once unfractionated heparin is discontinued during the acute phase of unstable angina, it has been demonstrated that the disease process may be reactivated within hours. It is hypothesized that this reactivation may be a result of direct platelet activation by heparin that can linger even after the drug itself has been stopped. Prior studies have shown that heparin can either increase or decrease platelet activation. More recent studies have also shown conflicting effects of unfractionated heparin on PFA-100 testing. Methods: We studied the in-vitro effects of unfractionated heparin on platelet function and PFA-100 testing. Unfractionated heparin was incubated with whole blood taken from 18 healthy volunteers. Platelet activation and aggregation was assessed with and without the presence of heparin. Results: Platelet aggregation and activation were increased in the presence of heparin. Unfractionated heparin also significantly prolonged collagen/adenosine diphosphate closure time but did not affect collagen/epinephrine closure time. Conclusions: Unfractionated heparin leads to direct platelet activation and increases platelet aggregation in vitro. Unfractionated heparin causes prolongation of the collagen/adenosine diphosphate closure time in PFA-100 testing, possibly as a result of direct binding to von Willebrand factor in solution and interference with von Willebrand factor-glycoprotein Ib binding.

KW - Heparin

KW - PFA testing

KW - Platelet function

UR - http://www.scopus.com/inward/record.url?scp=29344444026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344444026&partnerID=8YFLogxK

U2 - 10.1177/107424840501000407

DO - 10.1177/107424840501000407

M3 - Article

C2 - 16382263

AN - SCOPUS:29344444026

VL - 10

SP - 273

EP - 280

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 4

ER -